CA2219902A1 - Utilisation du 2-methyl-4-(4-methyl-1-piperazinyl)-10h-thieno¬2,3b|¬1,5|benzodiazepine pour le traitement du dysfonctionnement cognitif - Google Patents

Utilisation du 2-methyl-4-(4-methyl-1-piperazinyl)-10h-thieno¬2,3b|¬1,5|benzodiazepine pour le traitement du dysfonctionnement cognitif Download PDF

Info

Publication number
CA2219902A1
CA2219902A1 CA002219902A CA2219902A CA2219902A1 CA 2219902 A1 CA2219902 A1 CA 2219902A1 CA 002219902 A CA002219902 A CA 002219902A CA 2219902 A CA2219902 A CA 2219902A CA 2219902 A1 CA2219902 A1 CA 2219902A1
Authority
CA
Canada
Prior art keywords
methyl
piperazinyl
benzodiazepine
thieno
cognitive dysfunction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002219902A
Other languages
English (en)
Inventor
Charles Merritt Beasley Jr.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CA002219902A priority Critical patent/CA2219902A1/fr
Priority to AT95922148T priority patent/ATE220550T1/de
Priority to PL95323785A priority patent/PL189714B1/pl
Priority to JP8536420A priority patent/JPH11506096A/ja
Priority to EP95922148A priority patent/EP0828494B1/fr
Priority to PT95922148T priority patent/PT828494E/pt
Priority to PCT/US1995/006859 priority patent/WO1996038151A1/fr
Priority to HU9801173A priority patent/HUT77907A/hu
Priority to MX9707936A priority patent/MX9707936A/es
Priority to NZ288037A priority patent/NZ288037A/en
Application filed by Individual filed Critical Individual
Priority to AU26936/95A priority patent/AU707858B2/en
Priority to DE69527442T priority patent/DE69527442T2/de
Priority to DK95922148T priority patent/DK0828494T3/da
Priority to CZ19973243A priority patent/CZ292565B6/cs
Priority to ES95922148T priority patent/ES2180643T3/es
Priority claimed from PL95323785A external-priority patent/PL189714B1/pl
Publication of CA2219902A1 publication Critical patent/CA2219902A1/fr
Priority to NO19974766A priority patent/NO318553B1/no
Priority to FI973987A priority patent/FI973987A/fi
Priority to HK98110242A priority patent/HK1009393A1/xx
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Cette invention se rapporte à un procédé de traitement du dysfonctionnement cognitif qui consiste à administrer une quantité efficace de 2-méthyl-4-(4-méthyl-1-pipérazinyl)-10H-thiéno[2,3-b][1,5]benzodiazépine.
CA002219902A 1995-05-30 1995-05-30 Utilisation du 2-methyl-4-(4-methyl-1-piperazinyl)-10h-thieno¬2,3b|¬1,5|benzodiazepine pour le traitement du dysfonctionnement cognitif Abandoned CA2219902A1 (fr)

Priority Applications (18)

Application Number Priority Date Filing Date Title
AU26936/95A AU707858B2 (en) 1995-05-30 1995-05-30 Method for treating cognitive dysfunction
AT95922148T ATE220550T1 (de) 1995-05-30 1995-05-30 Verfahren zur behandlung von wahrnehmungsstörungen
JP8536420A JPH11506096A (ja) 1995-05-30 1995-05-30 認識機能不全を処置する方法
EP95922148A EP0828494B1 (fr) 1995-05-30 1995-05-30 Procede de traitement du dysfonctionnement cognitif
PT95922148T PT828494E (pt) 1995-05-30 1995-05-30 Compostos farmaceuticos
PCT/US1995/006859 WO1996038151A1 (fr) 1995-05-30 1995-05-30 Procede de traitement du dysfonctionnement cognitif
HU9801173A HUT77907A (hu) 1995-05-30 1995-05-30 2-Metil-4-(4-metil-piperazino)-1OH-tieno[2,3-b][1,5] benzodiazepin alkalmazása kognitiv diszfunkció kezelésére gyógyszerkészítmények előállítására
DE69527442T DE69527442T2 (de) 1995-05-30 1995-05-30 Verfahren zur behandlung von wahrnehmungsstörungen
NZ288037A NZ288037A (en) 1995-05-30 1995-05-30 Use of 2-methyl-4-(4-methyl-1-piperazinyl)-10h-thieno[2,3-b][1,5]benzo diazepine in the manufacture of a medicant for the treatment of alzheimer's disease
CA002219902A CA2219902A1 (fr) 1995-05-30 1995-05-30 Utilisation du 2-methyl-4-(4-methyl-1-piperazinyl)-10h-thieno¬2,3b|¬1,5|benzodiazepine pour le traitement du dysfonctionnement cognitif
PL95323785A PL189714B1 (pl) 1995-05-30 1995-05-30 Zastosowanie 2-metylo-4-(4-metylo-1-piperazynylo)-10H-tieno[2,3-b] [1,5]benzodiazepiny
MX9707936A MX9707936A (es) 1995-05-30 1995-05-30 Compuestos para tratar disfunciones del conocimiento.
DK95922148T DK0828494T3 (da) 1995-05-30 1995-05-30 Fremgangsmåde til behandling af kognitiv dysfunktion
CZ19973243A CZ292565B6 (cs) 1995-05-30 1995-05-30 Použití 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepinu k přípravě farmaceutického prostředku pro léčení kognitivní dysfunkce
ES95922148T ES2180643T3 (es) 1995-05-30 1995-05-30 Procedimiento para tratar la disfuncion cognitiva.
NO19974766A NO318553B1 (no) 1995-05-30 1997-10-15 Anvendelse av 2-metyl-4-(4-metyl-1-piperazinyl)-10H-tieno[2,3-b][1,5]benzodiazepin for behandling av en kognitiv dysfunksjon.
FI973987A FI973987A (fi) 1995-05-30 1997-10-17 Menetelmä kognitiivisen toimintahäiriön hoitamiseksi
HK98110242A HK1009393A1 (en) 1995-05-30 1998-08-26 Method for treating cognitive dysfunction

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CA002219902A CA2219902A1 (fr) 1995-05-30 1995-05-30 Utilisation du 2-methyl-4-(4-methyl-1-piperazinyl)-10h-thieno¬2,3b|¬1,5|benzodiazepine pour le traitement du dysfonctionnement cognitif
PL95323785A PL189714B1 (pl) 1995-05-30 1995-05-30 Zastosowanie 2-metylo-4-(4-metylo-1-piperazynylo)-10H-tieno[2,3-b] [1,5]benzodiazepiny
PCT/US1995/006859 WO1996038151A1 (fr) 1995-05-30 1995-05-30 Procede de traitement du dysfonctionnement cognitif
HU9801173A HUT77907A (hu) 1995-05-30 1995-05-30 2-Metil-4-(4-metil-piperazino)-1OH-tieno[2,3-b][1,5] benzodiazepin alkalmazása kognitiv diszfunkció kezelésére gyógyszerkészítmények előállítására
NO19974766A NO318553B1 (no) 1995-05-30 1997-10-15 Anvendelse av 2-metyl-4-(4-metyl-1-piperazinyl)-10H-tieno[2,3-b][1,5]benzodiazepin for behandling av en kognitiv dysfunksjon.

Publications (1)

Publication Number Publication Date
CA2219902A1 true CA2219902A1 (fr) 1996-12-05

Family

ID=27508637

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002219902A Abandoned CA2219902A1 (fr) 1995-05-30 1995-05-30 Utilisation du 2-methyl-4-(4-methyl-1-piperazinyl)-10h-thieno¬2,3b|¬1,5|benzodiazepine pour le traitement du dysfonctionnement cognitif

Country Status (1)

Country Link
CA (1) CA2219902A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005053703A1 (fr) * 2003-12-02 2005-06-16 Leslie James Sheldon Polytherapie contre la demence, la depression et l'apathie

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005053703A1 (fr) * 2003-12-02 2005-06-16 Leslie James Sheldon Polytherapie contre la demence, la depression et l'apathie

Similar Documents

Publication Publication Date Title
AU706471B2 (en) Process and crystal forms of 2-methyl-thieno-benzodiazepine
AU720366B2 (en) Olanzapine dihydrate D
EP0738514B1 (fr) Traitement des dyscinésies
EP0828494B1 (fr) Procede de traitement du dysfonctionnement cognitif
US5696115A (en) Method for treating nicotine withdrawal
US6432943B1 (en) Method for treating sexual dysfunction
US6506746B2 (en) Method for treating cognitive dysfunction
CA2219902A1 (fr) Utilisation du 2-methyl-4-(4-methyl-1-piperazinyl)-10h-thieno¬2,3b|¬1,5|benzodiazepine pour le traitement du dysfonctionnement cognitif
EP0831835B1 (fr) Traitement de l'anorexie
AU719517B2 (en) Method for treating excessive aggression
KR100366895B1 (ko) 인식기능장해치료용제약조성물
US6274636B1 (en) Method for treating a tic disorder
RU2176914C2 (ru) Способ лечения нарушения познавательной функции
US6071902A (en) Method for treating excessive aggression
CA2248758A1 (fr) Methode de traitement de l'insomnie

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued